psychopathology
Schizophrenia
- Prevalence: Schizophrenia affects approximately 1% of the population.
- Key symptom: Impaired logical thought.
Positive Symptoms of Schizophrenia
- Definition: Positive symptoms represent abnormal behaviors that are gained and include:
- Hallucinations: Perception of something that isn’t present.
- Delusions: Firmly held false beliefs that contradict reality.
- Excited motor behavior: Increased agitation or movement.
- Characteristics:
- Generally acute in onset.
- More likely to respond to antipsychotic medications.
Negative Symptoms of Schizophrenia
- Definition: Negative symptoms are characterized by a loss of functions and include:
- Slow thought and speech: Reduced responsiveness and communication.
- Emotional and social withdrawal: Decreased engagement and interaction with others.
- Blunted affect: Diminished emotional expression.
- Cognitive Symptoms:
- Disorganized thoughts, difficulty in concentrating, and challenges in following instructions.
Heritability of Schizophrenia
- Genetic factors play a role in schizophrenia susceptibility.
- Population statistics indicate varying risks based on familial connections:
- General population: 1%
- Spouses: 1%
- First cousins: 2%
- Uncles/Aunts: 2%
- Nephews/Nieces: 4%
- Grandchildren: 5%
- Half-siblings: 6%
- Children: 13%
- Siblings: 9%
- Siblings with one parent who has schizophrenia: 17%
- Dizygotic twins: 17%
- Parents: 6%
- Monozygotic twins: 48%
Brain Imaging and Schizophrenia
- MRI studies show discordant twins (one with schizophrenia, one without) have different ventricle-to-brain volume ratios.
- Findings:
- Patients with schizophrenia exhibit larger ventricles, indicating reduced brain volume.
Causes of Schizophrenia
- Schizophrenia arises from a combination of genetic vulnerabilities and environmental exposures.
- The illness is likely to develop if a genetic threshold is exceeded by environmental stressors.
- Environmental factors can upregulate or downregulate gene function and expression.
Environmental Factors
- Some potential environmental triggers include:
- Infectious agents (e.g., high influenza exposure during pregnancy).
- This can lead to increased birth rates of individuals with schizophrenia during high-flu years.
Brain Structure and Schizophrenia
- Hippocampus and Amygdala:
- These regions may be smaller in some individuals with schizophrenia.
- Pyramidal neurons in the hippocampus are often disorganized.
- Some individuals show a deficiency in Reelin, crucial for cell migration in the brain, correlating with symptoms.
Neurological Changes in Schizophrenia
- Accelerated Loss of Gray Matter:
- In adolescents diagnosed with schizophrenia, there is notable underactivity in the temporal and frontal lobes.
- Linked to accelerated aging and neuron loss, characterized as hypofrontality.
Dopamine Hypothesis
- Definition: Schizophrenia is associated with excess synaptic dopamine or increased postsynaptic sensitivity to dopamine.
- Evidence supporting this includes:
- Neuroleptics are dopamine antagonists.
- Chronic amphetamine usage can induce a schizophrenia-like syndrome.
- Treatment with L-dopa in Parkinson's can lead to psychotic symptoms.
- Increased D2 receptor levels are noted in the auditory thalamus of affected individuals.
Antipsychotic Drug Mechanisms
- All current antipsychotic medications modulate the function of the dopamine D2 receptor.
- Dosages required to block these receptors vary significantly among different antipsychotics.
Limitations of Dopamine Hypothesis
- Key issues include:
- Many schizophrenics exhibit normal dopamine metabolite levels.
- Drugs rapidly block dopamine receptors yet delay symptom relief.
- Not all positive symptoms respond to dopamine receptor antagonists.
Atypical Antipsychotics
- Examples include Risperidone and Abilify that block both serotonin (5-HT2) and D2 receptors.
- Some may also increase dopamine levels in the frontal cortex.
Glutamate Hypothesis of Schizophrenia
- The role of glutamate receptors (particularly NMDA) is crucial.
- PCP (Phencyclidine) is an NMDA antagonist and mimics acute schizophrenia symptoms through prolonged NMDA underactivation.
- Atypical antipsychotics may enhance glutamate signaling by downregulating the glutamate transporter gene.
Endocannabinoid System and Schizophrenia
- Overactivity of endocannabinoids (EC) occurs in schizophrenia.
- Elevated levels of endocannabinoids, particularly affecting CB1 receptors, inhibit other neurotransmitters.
- THC exposure in at-risk individuals can precipitate psychosis; worsening symptoms in diagnosed patients.
Other Mental Disorders
Depression
- Common mood disorder characterized by:
- Sad mood: Persistent feelings of sadness.
- Feelings of worthlessness or guilt: Self-criticism and low self-esteem.
- Loss of interest in pleasurable activities: Anhedonia.
- Appetite changes: Either increase or decrease in appetite; significant weight change.
- Sleep pattern alterations: Insomnia or hypersomnia.
- Suicidal ideation: Thoughts of self-harm or suicidal plans.
'Normal' vs. Clinical Depression
- Normal Depression:
- Reaction to life events, described as feeling 'blue'.
- Few symptoms and short duration (hours to days).
- Little to no impairment in functioning.
- Clinical Depression:
- Mood described as 'black', characterized by many symptoms and a long duration (weeks to months).
- Significant impairment in daily functioning, can be debilitating.
Neurobiology of Depression
- Increased activity in the emotional orbitofrontal cortex and amygdala; decreased in attention and language areas.
- Monoamine hypothesis: Proposes the cause of depression is reduced activity of norepinephrine and serotonin at synapses.
Treatment Modalities for Depression
- Antidepressants operate by:
- Inhibiting reuptake of serotonin (5-HT) or norepinephrine (NE).
- Binding to presynaptic 5-HT or NE autoreceptors to enhance neurotransmitter release.
- Inhibiting monoamine oxidase, reducing neurotransmitter breakdown.
Efficacy of Antidepressants
- Approximately 60% response rate seen in primary care settings.
- Overactive serotonin autoreceptors can impair release and contribute to depression; autoreceptor activity declines after weeks of SSRI treatment, increasing serotonin release and neuronal activity.
Electroconvulsive Therapy (ECT)
- Early findings indicated that seizure induction could alleviate depression.
- ECT parallels this effect by raising monoamine levels and is particularly used for severe depression associated with suicidal ideation.
- Short-term remission rate: 87%; long-term remission rate: 43%.
Brain Stimulation Treatments
- Transcranial Magnetic Stimulation (TMS): Non-invasive stimulation that produces effects resembling traditional ECT.
- Deep brain stimulation: Targets the anterior cingulate gyrus and median forebrain bundle, also showing immediate therapeutic effects.
- Vagus nerve stimulation: Gradual relief for depression symptoms.
Types of Antidepressants
- SSRI (Selective Serotonin Reuptake Inhibitors): First choice due to fewer severe side effects.
- SNRI (Selective Norepinephrine Reuptake Inhibitors)
- TCA (Tricyclics)
- MAO Inhibitors: Known to be effective but involve dietary restrictions and risk of hypertensive crisis.
Hypothalamic-Pituitary-Adrenal Axis in Depression
- The stress response involves complex interactions between the hypothalamus, pituitary gland, and adrenal glands, impacting cortisol levels.
- Cortisol levels can be significantly elevated in individuals with primary psychiatric disorders compared to normal controls.
Stress and Depression
- Neurotransmitter systems (glutamate and NMDA receptors) are impacted by stress.
- Exposure to stress contributes to synaptic dysconnectivity and diminishes overall neuronal function.
Ketamine in Depression
- Efficacy as an alternative treatment for severe depression; it shows a quick upsurge in glutamate, restoring synaptic function.
- Comparison with ECT shows efficacy in symptom relief.
Sleep Patterns in Depression
- Individuals with depression often have reduced and fragmented slow-wave sleep and enter REM sleep rapidly, often with increased REM prevalence.
Bipolar Disorder
- Characteristics: Fluctuation between depressive and manic states.
- Symptoms of mania include:
- Excess energy: Increased confidence and grandiosity.
- Reduced need for sleep: Patients may engage in hypersexual behavior or substance abuse.
Bipolar Disorder and Genetics
- Research suggests the involvement of specific genes (e.g., Clock gene) in the predisposition to bipolar disorder.
Cyclothymia
- A milder form of bipolar disorder, characterized by cycling between mild depression and hypomania.
Anxiety Disorders
- Phobic Disorders: Involves intense, irrational fear of specific objects or situations.
- Panic Disorder: Characterized by recurrent panic attacks marked by extreme fearfulness.
- Generalized Anxiety Disorder: Persistent and excessive worry about various aspects of life.
- Obsessive-Compulsive Disorder (OCD): Defined by recurrent intrusive thoughts (obsessions) and compulsive behaviors (compulsions) such as hand-washing.
Treatment for Anxiety Disorders
- Antidepressants help by reducing serotonin autoreceptor sensitivity.
- Benzodiazepines are commonly utilized for treating acute anxiety symptoms.
Neurobiology of Anxiety Disorders
- Patients with OCD exhibit increased activity in the orbitofrontal cortex and caudate nuclei.
- Surgery to disconnect the orbitofrontal cortex from the anterior cingulate cortex can lead to significant long-lasting improvements.
Tourette’s Syndrome
- Related to OCD, characterized by motor and phonic tics.
- Activation of the basal ganglia during tics is a prominent feature.
Historical Treatments in Psychiatry
- Frontal Lobotomy: Performed on various psychiatric disorders to induce remission but often resulted in severe personality changes.
- The technique used tools to create lobotomies that altered brain functioning, usually causing irreversible changes.